SynergyAnimal Cancer Care and Research Program

Winter 2010

From the director

Dr. Jaime Modiano

Dear ACCR Friends and Supporters:

After two years at the University of Minnesota, I am now able to look back briefly and take stock of where our program stands and where we are going.

In 2007, I joined a vibrant clinical program with a history of collaboration within the Veterinary Medical Center and across disciplines with our colleagues in other schools at the Academic Health Center. We formalized our relationship as an integrated part of the College of Veterinary Medicine and the Masonic Cancer Center in 2008, creating the Animal Cancer Care and Research (ACCR) program. With this first-of-its-kind effort, the faculty not only have “membership,” but the program is officially recognized as an integral component of the Masonic Cancer Center, our National Cancer Institute-designated Comprehensive Cancer Center. This provided resources and credibility to attract faculty, staff, and residents who have been recruited to the University through our program, as well as members who already were at the University and have a special interest in being part of the ACCR. You can find out more about the ACCR at www.cvm.umn.edu/accr/ and the Masonic Cancer Center at www.cancer.umn.edu/.

We are grateful to the leadership of the Academic Health Center, College of Veterinary Medicine, Masonic Cancer Center, Medical School, and College of Pharmacy for their vision and their assistance in making the ACCR a reality. We now stand at a crossroads for the future. Although we have been able to grow our program during this time of unprecedented economic challenges and cutbacks in government funding for research, the future is uncertain. Right now, we can point to our amazing program in experimental therapeutics for brain cancer, led by Drs. John Ohlfest and Liz Pluhar, as an area where we have staked our position of national leadership with unprecedented success, exemplified by Batman and several other canine patients with spontaneous brain tumors that have beat the odds thanks to the efforts of the brain cancer team. (You can learn more about Batman and the canine brain tumor clinical trials at www.cvm.umn.edu/newsarchives/2009/braintumortrials/.) Nevertheless, the sustainability of our program will require innovative approaches to enhance our endowments, diversify and grow our grant portfolio, develop new collaborations with the private sector, and work with our supporters to provide advocacy and increase philanthropic support.

Our record of leadership and success is just beginning. ACCR members are involved in many other such projects that will help bring knowledge and technology from the laboratory to the clinic – and back. In this issue of Synergy, you will read about two exciting research programs that are part of our wholistic approach to preventing and curing cancer in companion animals and in people alike. We also introduce our newest members and bring back the “clinical case study” section that was so well received in our previous newsletter.

I hope you enjoy reading about our program. We are excited about our future and would like you to join us on this journey of hope and success.

Sincerely,

Jaime

Jaime F. Modiano, V.M.D., Ph.D.Perlman Professor of Animal OncologyDirector, Animal Cancer Care and Research Program

Synergy Animal Cancer Care and Research Program

Clinical case study

Jake, a 7-year-old neutered male chocolate Labrador retriever, started limping on his left front leg after

playing in the yard. A veterinary exam found that the pain originated in Jake’s left shoulder. Pain medications and several days of rest were somewhat beneficial, but the lameness persisted.

X-rays reveal destruction of the humerusX-rays of the shoulder were then performed, revealing destruction of the humerus, one of the bones associated with the shoulder.

Based on the location and appearance of the bone lesion, a cancerous process was strongly suspected. The most common bone cancer in dogs is osteosarcoma, an aggressive cancer. In most dogs diagnosed with osteosarcoma, the cancer has spread to other sites in the body at the time it is diagnosed. For many patients, the diagnosis is confirmed through a biopsy from the abnormal bone. Because clinicians highly suspected osteosarcomea based on the location and the appearance on radiographs, Jake did not have a biopsy. Radiation therapy and medication control painJake underwent palliative radiation therapy using three doses of radiation over three weeks, with the goal of alleviating the pain associated with the bone lesion. His limping improved dramatically after treatment.

The radiation treatment, along with medications for pain, helped control Jake’s pain for six months. Then Jake began to limp again: The pain was back. Jake underwent three additional radiation therapy treatments. This second course of radiation therapy again helped to control his pain and improved his quality of life for another seven months. When the pain recurred again, Jake was euthanized.

Pain control for osteosarcoma using radiation therapy is successful in about 85

percent of patients. For the average patient with osteosarcoma, the length of time that radiation therapy is helpful is about six months. As a result of his treatments,Jake enjoyed a dramatic increase in his quality of life for 13 months.

A radiograph of a healthy shoulder

Jake’s shoulder radiograph reveals the area of bone destruction.

2 • Synergy Winter 2010

Jake

Cancer researchers seek partnership with Minnesota veterinarians What are the origins of cancer? Which dogs get the disease? Why are some breeds more susceptible than others? Do heredity, birth weight, growth rate, diet, exercise, and environmental exposures play a role?

University of Minnesota faculty and Masonic Cancer Center members Jaime Modiano, who studies oncology and comparative medicine at the College of Veterinary Medicine, and Logan Spector, who studies cancer epidemiology at the School of Medicine, are teaming up to answer these questions, and are looking for community veterinarians to collaborate with them.

“Pet dogs are an ideal species in which to conduct lifelong epidemiologic studies of cancer, since they share the human environment, develop cancer at roughly the same rate as humans, have available a high-quality genome sequence, and have a lifespan that is short enough to allow birth-to-death observation,” says Spector. “We would like to work with Minnesota veterinarians on a long-term exploration of canine cancer.”

Interested in learning more? Jaime and Logan are planning to host an informational breakfast or early evening meeting with interested veterinarians. To learn more, contact Logan Spector at spector@umn.edu or 612-624-3912.

Synergy Animal Cancer Care and Research Program

Dr. Catherine St. Hill explores mechanisms of cancer cell metastasisDr. Catherine

St. Hill’s laboratory

studies the molecular mechanisms involved in the attachment of cancer cells to blood vessels and their growth and spread into surrounding tissues.

Cancer cells and white blood cells share many characteristics between the steps of cancer spread from the initial tumor to distant body sites and white blood cell movement from the blood to areas of inflammation in tissues. Both cell types circulate in the bloodstream and interact with the blood vessel wall to facilitate exit from the blood and entry into tissues. Cancer cells express particular carbohydrate molecules that promote much stronger binding to the blood vessel than would typically be observed when white blood cells bind during inflammation. This feature may facilitate the entry of cancer cells into normal tissues.

Dr. St. Hill’s laboratory investigates the importance of carbohydrates expressed by cancer cells in the development and spread of cancer and the association with survival of the cancer patient (humans and animals). These carbohydrates are expressed on many different types of cancer cells, but are not present in normal tissues. Increased carbohydrate expression is associated with a more advanced progression of human cancers, and in some cases predicts cancer progression.

Dr. St. Hill has demonstrated that cancers that affect both humans and dogs highly express these carbohydrates and promote attachment to blood vessels, and that

SynergySynergy is designed to provide you with information about the research and treatment efforts of the

College of Veterinary Medicine’s Animal Cancer Care and Research program and how these efforts may be of service to you and the animals you care about.

The Animal Cancer Care and Research program is part of the University of Minnesota College of Veterinary Medicine and Masonic Cancer Center. Its mission is to advance knowledge in cancer biology

that can be translated and implemented into treatment that will reduce the incidence of cancer and improve the outcomes for animals and humans with cancer. For more information about the

Animal Cancer Care and Research program, visit www.cvm.umn.edu/accr.

Published by the University of Minnesota Animal Cancer Care and Research programCopy editing and design: Sue KirchoffCopyright 2009. All rights reserved.

The University of Minnesota is an equal-opportunity educator and employer.

3 • Synergy Winter 2010

the presence of these carbohydrates increases the ability of cancer cells to invade tissues. She is examining the interactions of carbohydrate-expressing cancer cells with inflammatory cells in tumors to determine whether these interactions allow tumors to spread more aggressively into tissues. The development of strategies to disrupt expression of these carbohydrates on the cancer cell surface may be useful therapeutically to slow or eliminate cancer growth and spread.

A scanning electron micrograph of a metastatic cancer cellImage courtesy of the National Cancer Institute

Catherine St. Hill

Follicular thyroid cancerWe need to learn more about this devastating disease

By Vicki Wilke, D.V.M., Ph.D., DACVS

Thyroid cancer is a relatively uncommon disease, affecting approximately one percent

of humans and dogs. However, its significance lies in the fact that, in both species, follicular thyroid cancer is very aggressive and is associated with more devastating outcomes than are other types of cancer.

There is increasing evidence that the dog may be an appropriate model for human thyroid cancer since there are many common factors, including increased risk with age, links to thyroid gland inflammation, and treatment options.

Dogs are often brought to the clinic because the owner noticed a mass in the neck or other symptoms such as coughing and difficulty breathing and swallowing. Tumors spread rapidly to surrounding structures in the neck and via the bloodstream to organs such as the lungs, kidneys, and brain. In fact, for a large proportion of dogs, there is already distant spread at the time of diagnosis. Since follicular thyroid cancer is more common in older dogs, available treatments such as surgery, radiation therapy, and chemotherapy often cause complications and sometimes death.

Studies aim to learn more about canine thyroid cancerThere is a lot of information on the genetic features of human thyroid cancer, but little is known about canine thyroid cancer. It is important to understand the molecular changes, since they are ultimately responsible for supporting tumor progression. Our studies are based on the premise that information learned from a sample of dogs will be applicable to the targeted population. We extract genetic information from blood and surgically removed thyroid tumors to study differences in the expression of thousands of genes in affected dogs compared to dogs with normal thyroid glands. This

generates gene patterns that are associated with disease severity and is used to select the genes that will give us the most information and the ability to discriminate between normal and abnormal with high sensitivity.

Discovering the genes that are responsible for this disease will allow us to –

Screen apparently healthy dogs to • determine their risk of developing follicular thyroid cancer

Diagnose at an earlier stage dogs that • already have follicular thyroid cancerPredict how a particular tumor will • behaveMonitor the response to treatment •

Translational research (benchtop-to-bedside/cageside) will allow us to apply what we learn in the laboratory to clinical management of future canine patients and to extrapolate our findings to advance human therapy.

Synergy Animal Cancer Care and Research Program

4 • Synergy Winter 2010

Dr. Vicki Wilke examines a patient at the University of Minnesota Veterinary Medical Center. Photo by Sue Kirchoff

Synergy Animal Cancer Care and Research Program

5 • Synergy Winter 2010

ACCR welcomes new faculty and staffClaire Cannon, BVSc, started her three-year oncology residency in July. Claire made a long journey to join the Oncology Service: She comes to us from Australia. A graduate of the doctor of veterinary medicine program at the University of Melbourne, she had two years experience in a mixed practice and then completed a one-year internship in Sydney. Outside of work, she enjoys hiking, reading, and live music.

Erin B. Dickerson, Ph.D., joined the Veterinary Clinical Sciences Department and Masonic Cancer Center as assistant professor in October. Previously a scientist with the School of Biology at Georgia Institute of Technology in Atlanta, Erin earned her PhD. in biochemistry at the University of Wisconsin-Madison, where she did postdoctoral work in oncology at the School of Veterinary Medicine. An accomplished researcher, she has published journal articles in many veterinary and cancer research publications, made presentations at a variety of national and international conferences, and has several patents to her name.

Julie McClure, CVT, is the newest technician to join the Oncology Service. She comes to us with two years experience in the Veterinary Medical Center’s intensive care unit. A graduate of Argosy University, Julie enjoys constant learning and takes a variety of classes outside of work.

WillPower Fund launched to raise funds for ACCR program

On August 5, 2009, the WillPower Fund was launched to support comparative oncology research

at the University of Minnesota AACR program.

Dave and LuAnn Runkle, longtime members of the Greater Twin Cities Golden Retriever Club and friends of the University of Minnesota and Veterinary Medical Center, lost their beloved golden retriever William to cancer. This loss, as well as many other cherished goldens, inspired the creation of the WillPower Fund, which supports research in comparative oncology with special emphasis on the human-canine connection in cancer research and treatment.

The inaugural event at the College of Veterinary Medicine’s Pomeroy Student-Alumni Learning Center saw a gathering

of more than 40 friends and supporters for dinner, a presentation about the program, and a question-and-answer session.

“The support we receive from friends at the WillPower Fund is vital to help us achieve our goal to eradicate cancer in animals and humans,” says Jaime Modiano, ACCR director.

For information about how you can support the WillPower Fund in its efforts to conquer cancer, please contactBill Venne at 612-625-8489 orvenne025@umn.edu.

Aric Frantz awarded Morris Animal Foundation fellowship

Aric Frantz, center, a Ph.D. candidate in the College of Veterinary Medicine’s comparative and molecular biosciences graduate program, with his mentors, Tim O’Brien, professor in the Veterinary Population Medicine Department, and Jaime Modiano, professor of comparative oncology and director of the Animal Cancer Care and Research program.

Aric Frantz, a Ph.D. candidate in the College of Veterinary Medicine’s comparative and molecular biosciences graduate program, has been awarded a two-year fellowship by the Morris Animal Foundation. The $93,000 fellowship supports Aric’s project entitled “Enrichment for Canine Cancer Stem Cells by In Vitro Manipulation and Chemotherapy.”

Synergy Animal Cancer Care and Research Program

Animal Cancer Care and Research Program members have received funding for the following new research grants. Congratulations!

Canine Non-Hodgkin Lymphoma: Characterization and Prognostic Value of Cancer Stem CellsInvestigators: Tim O’Brien and Jaime ModianoFunding agency: AKC Canine Health Foundation Period of award: 01/01/09-12/31/10Award amount: $150,393Goal: To determine if there is a “cancer stem cell” compartment that is essential for the origin and progression of lymphoma.

Comparative Medicine and Pathology TrainingInvestigator: Cathy Carlson Funding agency: National Center for Research Resources, NIH Period of award: 07/01/09-06/30/14This is an institutional training grant to support four veterinarians working toward Ph.D. degrees. The training will prepare them for careers as independent scientists.

Define the Role of Macrophage ADAM17 in Mammary TumorigenesisInvestigators: Bruce Walcheck, Catherine St. Hill, Kaylee Schwertfeger, Kelly HallFunding agency: CVM Comparative Medicine Signature Program grantPeriod of award: 12/31/09-12/31/11Award amount: $60,000Goal: To investigate the role of macrophage-expressed ADAM17 in the regulation of tumor formation and metastasis in mammary epithelial cells and breast carcinomas.

Defining the Nuclear Progesterone Receptor as an Anti-Proliferative, Pro-Apoptotic Tumor Suppressor of Ovarian CancerInvestigator: Carol LangeFunding agency: Minnesota Ovarian Cancer AlliancePeriod of award: 8/01/09-07/31/10Award amount: $60,000Goal: To understand mechanisms of ovarian cancer cell regulation by progesterone.

Genetic Background and the Angiogenic Phenotype in CancerInvestigators: Jaime Modiano and Leslie SharkeyFunding agency: AKC Canine Health Foundation

Period of award: 01/01/10-12/31/12Award Amount: $235,399Goal: To determine how genetic background and heritable traits (defined by breed) influence the tumor and its microenvironment in canine hemangiosarcoma.

Improving Delivery of Molecularly – Targeted Therapy to Invasive Glioma CellsInvestigators: John Ohlfest and Bill ElmquistFunding agency: National Cancer Institute, NIHPeriod of award: 04/01/10-03/31/15Award amount: $1,919,186 total costsGoal: The blood brain barrier (BBB) restricts the influx of drugs into normal brain structures where glioma cells typically infiltrate. The BBB has mechanical (size exclusion) and active mechanisms (ATP-dependent drug transporters) to exclude drugs and antibodies from entrance. This project is designed to develop new methods to deliver drugs to the tumor, or to overcome immune suppression at the tumor site, while minimizing side effects to normal brain cells.

Isolation and Characterization of Canine Cancer Stem CellsInvestigator: Aric FrantzFunding agency: Morris Animal FoundationPeriod of award - 07/01/09-06/30/11This is an individual fellowship award to support the Ph.D. component of Aric Frantz’s dual degree (D.V.M./Ph.D.) program.

Isolation and Characterization of Canine Peripheral Blood Natural Killer CellsInvestigator: Helen MichaelFunding agency: CVM Small Companion Animal GrantsPeriod of award: 07/01/09-06/30/10Award amount: $7,450Goal: To define canine NK cells functionally and phenotypically to establish a platform for comparative studies using NK cell therapy for cancer.

Lung Cancer Chemoprevention by Indole-3-carbinolInvestigator: Fekadu KassieFunding agency: National Cancer Institute, NIHPeriod of award: 02/01/09-12/31/14Award amount (yearly): $250,660Goal: To develop indole-3-carbinol as a chemopreventive agent against lung cancer in current and former smokers.

6 • Synergy Winter 2010

New research grants

Synergy Animal Cancer Care and Research Program

7 • Synergy Winter 2010

Molecular Characterization of Osteosarcoma: A Comparative Genomics ApproachInvestigators: Subbaya Subramanian, Jaime ModianoFunding agency: University of Minnesota Academic Health Center Faculty Research Development AwardPeriod of award: 01/01/09-12/31/10Award amount: $200,000Goal: To define molecular abnormalities that are shared between human and canine osteosarcoma to better understand the etiology of the disease, define clinically relevant subtypes, and identify novel therapeutic targets.

Neuro-Oncology Genomics ProjectInvestigator: David LargaespadaFunding agency: National Brain Tumor SocietyPeriod of Award: 10/01/09-09/31/12Award amount (yearly): $186,000Goal: To utilize Sleeping Beauty as random somatic cell insertional mutagenesis system for brain tumor mutagenesis in wild-type, NMYC overexpressing, and IDH1 mutant backgrounds for the purpose of identifying candidate medulloblastoma and glioma cancer genes.

New Fluorescent Caspase Detection Probes to Label Apoptotic Tumor Cells in VivoInvestigators: Brian W. Lee, Catherine St. HillFunding agency: NIH/NCI/SBIRPeriod of award: 09/08-09-08/31/10Award amount: $700,067Goal: To evaluate the ability of fluorochrome-conjugated probes to detect apoptotic tumor cells in vivo using five different tumor model systems.

Preclinical Evaluation of Two-Photon-Targeted Photodynamic Therapy TriadsInvestigator: Antonella BorgattiFunding agency: ACVIM FoundationPeriod of award: 07/01/09-06/30/10Award amount: $15,000Goal: To develop a model that will justify the application of photodynamic therapy to treat cancer in companion animals.

Proteomics Analysis of Metastasis–Associated Proteins in Human and Canine Osteosarcoma CellsInvestigator: Fekadu KassieFunding agency: American Cancer Society Institutional Grant AwardPeriod of award: 01/01/09-12/31/09

Award amount: $30,000Goal: To identify biomarkers for metastasis that could be potentially used as markers for diagnosis, prognosis, and therapy response.

Residency Training in Veterinary Oncology at the University of MinnesotaTrainee: Claire Cannon Funding agency: Morris Animal FoundationPeriod of award: 07/01/09-06/30/12This fellowship award provides support for Dr. Claire Cannon during her oncology residency in preparation to achieve board certification by the American College of Veterinary Internal Medicine (specialty of Oncology).

Role of NK Cells in Enhancing Brain Tumor ImmunotherapyInvestigator: John OhlfestFunding agency: American Cancer SocietyPeriod of award: 01/01/09-06/31/11Award amount: $720,000 total costsGoal: Some types of brain cancer develop strategies to avoid immune recognition. These studies will examine the molecular basis for immune escape and determine how the natural killer arm of the immune system can circumvent resistance to T-cell immunity. The grant culminates in a clinical trial conducted in pet dogs with spontaneous gliomas. Dogs will be treated with the combination of gene therapy (recruits NK cells into tumor) and vaccination that primes a T cell response against the tumor. These studies could have important translational significance, since the use of dogs with naturally occurring tumors can establish the efficacy of this combination therapy as a prelude to human studies.

Targeting p21 to Increase Chemosensitivity in Breast CancerInvestigators: Jaime Modiano, Robert Weiss (University of California, Davis)Funding agency: Masonic Cancer Center, University of Minnesota Translational Breast Cancer Research AwardPeriod of award: 07/01/09-06/30/10Award amount: $25,000Goal: To determine whether reducing the p21 protein will increase the apoptotic tendency of progesterone-dependent mammary cancer, which is a highly malignant form seen in women and the most common form seen in cats, as a means to make these tumors more sensitive to conventional chemotherapy drugs.

More new research grants

Synergy Animal Cancer Care and Research Program

8 • Synergy Winter 2010

“Anti-tumor Responses in Dogs with Spontaneous Astrocytoma and Papillary Meningioma Treated by Immunotherapy,” by G. Elizabeth Pluhar, Wei Chen, Patrick T. Grogan, Charlie Seiler, Mike Olin, Cathy Carlson, Karen A. SantaCruz, Maria G. Castro, Pedro R. Lowenstein, Stephen Haines, Matthew A. Hunt, and John R. Ohlfest was presented at the annual meeting of the Society for Neuro-Oncology in New Orleans in October.

“Integrated Actions of Progesterone Receptors and Cell Cycle Machinery Regulate Breast Cancer Cell Proliferation,” by G.E. Dressing and C.A. Lange, was published in Steroids in December 2008, online at http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TC9-4V47CGN-1&_user=616288&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000032378&_version=1&_urlVersion=0&_userid=616288&md5=1e7c251069eac0f992e7028e51c9b09e

“Nicotine-Mediated Signals Modulate Cell Death and Survival of T Lymphocytes,” by Silvia C.S. Oloris, Ashley A. Frazer-Abel, Cristan M. Jubala, Susan P. Fosmire, Karen M. Helm, Sally R. Robinson, Derek M. Korpela, Megan M. Duckett, Shairaz Baksh, and Jaime F. Modiano, to be published in Toxicology and Applied Pharmacology, is available online at www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WXH-4XM6K6W-1&_user=616288&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000032378&_version=1&_urlVersion=0&_userid=616288&md5=5e3e822ee285eaadb515e41a8ca0d081.

“Protein Kinases Mediate Ligand-Independent Derepression of Sumoylated Progesterone Receptors in Breast Cancer Cells,” by A.R. Daniel and C.A. Lange, was published in the Proceedings

Transposon-based screens for colorectal cancer genesInvestigator: David LargaespadaFunding agency: National Cancer Institute, NIH Period of award: 04/01/09-03/31/14Award amount (yearly): $250,000Goal: To utilize Sleeping Beauty as random somatic cell insertional mutagenesis system for gastrointestinal track mutagenesis in wild-type, p53-deficient, and APC-deficient mice for the purpose of identifying candidate colorectal cancer genes.

2-Amino-9H-pyrido[2,3-b]indole: a Potential Colorectal Carcinogen Formed in Tobacco SmokeInvestigators: Fekadu Kassie, Robert Turesky (New York State Department of Health)Funding agency: National Cancer Institute, NIHPeriod of award: 02/01/10-01/31/12Award amount: pending federal budgetGoal: To determine whether 2-amino-9H-pyrido-[2,3-b]indole (AαC), a tobacco-smoke constituent, is causally related to colorectal cancer in smokers, and to elucidate the mechanistic pathways underlying this exposure-cancer relationship.

Publications and presentationsof the National Academy of Sciences in August 2009, online at http://www.pnas.org/content/106/34/14287.full?sid=b40daa24-1870-42d6-9020-b412d470360a

“Scaffolding Actions of Membrane-Associated Progesterone Receptors,” by C.R. Hagan, E.J. Faivre, and C.A. Lange, was published in Steroids in December 2008, online athttp://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6TC9-4V70NGM-1&_user=616288&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000032378&_version=1&_urlVersion=0&_userid=616288&md5=39661c9546a4ed007fa4b73e81eb992a

“S-MED: Sarcoma MicroRNA Expression Database,” byA. Sarver, R. Phalak, V. Thayanithy, and S. Subramanian, has been accepted for publication in Laboratory Investigation, an official journal of the United States and Canadian Academy of Pathology.

“The High Affinity Selectin Glycan Ligand C2-0-sLeX and mRNA Transcripts of the Core 2 Beta-1,6-N-Acetylglucosaminyltransferase (C2GnT1) Gene are Highly Expressed in Human Colorectal Adenocarcinomas,” by Catherine A. St. Hill, Mariya Farooqui, Gregory Mitcheltree, H. Evin Gulbahce, Jose Jessurun, Qing Cao, and Bruce Walcheck, was published in BMC Cancer on March 6, 2009. The article is online at www.biomedcentral.com/1471-2407/9/79.

“The Novel Carbohydrate Tumor Antigen C2-O-sLex is Upregulated in Canine Gastric Carcinomas,” by Laura Janke, Cathy S. Carlson, and Catherine A. St. Hill, has been accepted for publication in the May 2010 issue of Veterinary Pathology.

More new research grants